Astrana Health, Inc.

How big is Astrana Health, Inc.?

As of Jun 18, Astrana Health, Inc. has a market capitalization of 1,475.48 million, with net sales of 2,250.57 million and a net profit of 39.29 million over the latest four quarters.

Market Cap: As of Jun 18, Astrana Health, Inc. has a market capitalization of 1,475.48 million, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Astrana Health, Inc. reported net sales of 2,250.57 million and a net profit of 39.29 million.<BR><BR>Balance Sheet Snapshot: As of Dec'24, the company reported shareholder's funds of 712.72 million and total assets of 1,375.55 million.

What does Astrana Health, Inc. do?

Astrana Health, Inc. is a physician-centric integrated population health management company with net sales of $620 million and a net profit of $6 million as of March 2025. It has a market cap of approximately $1.48 billion and key metrics include a P/E ratio of 36.00 and a debt-to-equity ratio of 0.22.

Overview: <BR>Astrana Health, Inc. is a physician-centric integrated population health management company operating in the miscellaneous industry and categorized as a small-cap entity.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 620 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 6 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 1,475.48 Million (Small Cap)<BR><BR>Key Metrics: <BR>P/E: 36.00 <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.22 <BR>Return on Equity: 5.30% <BR>Price to Book: 1.98<BR><BR>Contact Details: <BR>Address: 1668 S Garfield Ave Fl 2nd, ALHAMBRA CA: 91801-5474 <BR>Tel: 1 626 2820288 <BR>Fax: 1 818 8395190 <BR>Website: http://apollomed.net

Who are in the management team of Astrana Health, Inc.?

As of March 2022, the management team of Astrana Health, Inc. includes Dr. Kenneth Sim (Chairman and Co-CEO), Dr. Thomas Lam (President and Co-CEO), and several directors including Mr. Mitchell Kitayama (Lead Independent Director), Ms. Linda Marsh, Mr. Matthew Mazdyasni, Dr. Ernest Bates, and Mr. John Chiang. They oversee the company's operations and strategic direction.

As of March 2022, the management team of Astrana Health, Inc. includes the following individuals:<BR><BR>- Dr. Kenneth Sim: Chairman of the Board, Co-Chief Executive Officer, Executive Director<BR>- Dr. Thomas Lam: President, Co-Chief Executive Officer, Director<BR>- Mr. Mitchell Kitayama: Lead Independent Director<BR>- Ms. Linda Marsh: Director<BR>- Mr. Matthew Mazdyasni: Director<BR>- Dr. Ernest Bates: Independent Director<BR>- Mr. John Chiang: Independent Director<BR><BR>This team is responsible for overseeing the company's operations and strategic direction.

Should I buy, sell or hold Astrana Health, Inc.?

Is Astrana Health, Inc. technically bullish or bearish?

As of August 8, 2025, Astrana Health, Inc. shows a mildly bearish trend overall, with mixed technical indicators across time frames and significant underperformance compared to the S&P 500.

As of 8 August 2025, the technical trend for Astrana Health, Inc. has changed from bearish to mildly bearish. The weekly MACD is mildly bullish, while the monthly MACD is bearish, indicating mixed signals across time frames. The Bollinger Bands also show a mildly bullish stance on the weekly chart but are bearish on the monthly. Daily moving averages are mildly bearish, and the KST is bullish weekly but bearish monthly. Overall, the Dow Theory indicates a mildly bearish trend on the weekly basis with no trend monthly. <BR><BR>In terms of performance, Astrana Health has underperformed compared to the S&P 500 across multiple periods, with a year-to-date return of -5.52% versus the S&P 500's 12.22%, and a one-year return of -47.88% compared to 17.14% for the index. This suggests a weak technical stance overall, with bearish tendencies prevailing despite some mildly bullish indicators on shorter time frames.

Is Astrana Health, Inc. overvalued or undervalued?

As of October 17, 2025, Astrana Health, Inc. is considered very expensive with a P/E ratio of 36, significantly higher than its peers, and has underperformed the S&P 500 with a year-to-date return of 1.52% and a one-year return of -47.84%.

As of 17 October 2025, the valuation grade for Astrana Health, Inc. has moved from expensive to very expensive, indicating a significant increase in perceived overvaluation. The company appears to be overvalued based on its current metrics, particularly with a P/E ratio of 36, which is substantially higher than peers like Premier, Inc. at 11.29 and Select Medical Holdings Corp. at 7.26. Additionally, the EV to EBITDA ratio stands at 14.41, further suggesting that the company's valuation is not justified by its earnings potential.<BR><BR>Comparing Astrana Health's performance to the S&P 500, the stock has shown a year-to-date return of 1.52%, significantly lagging behind the index's 13.30% return, and a one-year return of -47.84% compared to the S&P 500's 14.08%. This underperformance reinforces the notion that Astrana Health, Inc. is overvalued in the current market environment.